Lmr Partners LLP Glycomimetics Inc Transaction History

Lmr Partners LLP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$2.55 - $3.49 $35,960 - $49,215	14,102 New	14,102 $42,000
Q3 2021 Nov 15, 2021	SELL	$1.8 - $2.39 $41,200 - $54,704	-22,889 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$2.16 - $3.18 $49,440 - $72,787	22,889 New	22,889 $53,000
Q1 2021 May 17, 2021	SELL	$2.89 - $4.22 $30,423 - $44,423	-10,527 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$2.69 - $4.24 $12,137 - $19,130	-4,512 Reduced 30.0%	10,527 $40,000
Q2 2020 Aug 14, 2020	BUY	$2.06 - $3.76 $30,980 - $56,546	15,039 New	15,039 $57,000

17.7M

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $13.1M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Lmr Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Lmr Partners LLP with notifications on news.